Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient

被引：17
|
作者：
Mercadal, L [1 ]
Foltz, V [1 ]
Isnard-Bagnis, C [1 ]
Ourahma, S [1 ]
Deray, G [1 ]
机构：
[1] Hop La Pitie Salpetriere, Dept Nephrol, F-75013 Paris, France
来源：
TRANSPLANTATION PROCEEDINGS | 2005年 / 37卷 / 10期
关键词：
D O I：
10.1016/j.transproceed.2005.11.010
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We report the third case in the literature of a patient with a long-lasting renal allograft who experienced tuberculosis just after the switch from azathioprine to mycophenolate mofetil. The switch was likely responsible for the reactivation of dormant tuberculosis; prophylactic antituberculous treatment should be considered in cases of such a therapeutic change.
引用
收藏
页码：4241 / 4243
页数：3
相关论文
共 50 条
  • [21] FAVORABLE LONG-TERM EFFECTS OF MYCOPHENOLATE MOFETIL (CellCept®) INTRODUCTION IN PEDIATRIC RENAL TRANSPLANT PATIENTS
    Pape, Lars
    Toenshoff, Burkhard
    Doetsch, Joerg
    Holm, Alberto
    Burkhalter, Sigrid
    Meier-Kriesche, Herwig-Ulf
    TRANSPLANT INTERNATIONAL, 2009, 22 : 88 - 88
  • [22] Improvement in long-term graft survival in cadaveric renal transplant recipients treated with mycophenolate mofetil
    Hazzan, M
    Provot, F
    Glowacki, F
    Copin, MC
    Roumilhac, D
    Labalette, M
    Pruvot, F
    Noel, C
    TRANSPLANT INTERNATIONAL, 2004, 17 (09) : 525 - 530
  • [23] Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy
    Chiarelli, Laurent R.
    Molinaro, Mariadelfina
    Libetta, Carmelo
    Tinelli, Carmine
    Cosmai, Laura
    Valentini, Giovanna
    Dal Canton, Antonio
    Regazzi, Mario
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (01) : 38 - 50
  • [24] Long-term pharmacokinetics of mycophenolate mofetil (MF) suspension in pediatric renal transplant recipients.
    Weber, LT
    Hoecker, B
    Bunchman, T
    Rashford, M
    Toenshoff, B
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 66 - 66
  • [25] Azathioprine vs. mycophenolate mofetil in geriatric renal transplant recipients
    Meier-Kriesche, HU
    Jacobs, M
    Mulgaonkar, S
    Friedman, G
    Vaghela, M
    Thambuganipalle, R
    Haq, N
    Kaplan, B
    TRANSPLANTATION, 1999, 67 (07) : S233 - S233
  • [26] Long-term safety and tolerability after conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic) in stable maintenance renal transplant recipients
    Chapman, J
    IMMUNOLOGY AND CELL BIOLOGY, 2006, 84 (03): : A7 - A7
  • [27] Primary tuberculosis 1 year after conversion from azathioprine to mycophenolate in recipient kidney transplantation: A case report
    Skhiri, H
    Guedri, Y
    Souani, Y
    Achour, A
    Bouraoui, S
    Frih, A
    Dhia, BN
    Elmay, M
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (07) : 2678 - 2679
  • [28] Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine
    Taylor, DO
    Sharma, RC
    Kfoury, AG
    Renlund, DG
    CLINICAL TRANSPLANTATION, 1999, 13 (04) : 296 - 299
  • [29] Increased incidence of allograft rejection in stable heart transplant recipients after conversion from mycophenolate mofetil to azathioprine.
    Sharma, RC
    Kfoury, AG
    Taylor, DO
    DunnDrager, D
    Renlund, DG
    CIRCULATION, 1997, 96 (08) : 346 - 346
  • [30] Mycophenolate mofetil/prednisolone/tacrolimusMumps in a renal transplant recipient: case report
    Reactions Weekly, 2008, 1221 (1) : 23 - 23
12345